SGLT-2 inhibitors in development for type 2 diabetes treatment - Wikidata - awgldk - TriplyDB

SGLT-2 inhibitors in development for type 2 diabetes treatment

SGLT-2 inhibitors in development for type 2 diabetes treatment

http://www.wikidata.org/entity/Q34248505

about

Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.A Review on the Relationship between SGLT2 Inhibitors and Cancer.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.The vascular endothelium in diabetes--a therapeutic target?Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.The central question of type 2 diabetes.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.

P2860

Q26866958-E84DA691-89FD-47B3-B871-48A8DA57F6AA Q30833760-4A4B67CE-9AA2-4073-9F34-47E2BF0D7AD2 Q33785128-A747F052-7FAC-4B74-8B05-E48441C86D0E Q34181385-A7F2F25E-8AFF-4B9E-8866-E049104406DE Q35049845-7DC5D3B1-7FAF-4213-A29B-D1C8E6F24B19 Q35760275-2D6F47B5-5B8A-4B9C-8524-94B291EB7C12 Q36673550-91502F7B-07DF-49A7-B071-997BD5881117 Q38130748-B9B31508-514D-4B21-A4B9-69ED0CCB9303 Q38162978-29E7CE26-8A30-4482-9B01-7F43EA701B62 Q38663903-2C164530-9AAD-4D2F-BEDE-50B0E932D1AD

P2860

SGLT-2 inhibitors in development for type 2 diabetes treatment

http://www.wikidata.org/entity/Q34248505

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

SGLT-2 inhibitors in development for type 2 diabetes treatment

@ast

SGLT-2 inhibitors in development for type 2 diabetes treatment

@en

SGLT-2 inhibitors in development for type 2 diabetes treatment

@nl

type

label

SGLT-2 inhibitors in development for type 2 diabetes treatment

@ast

SGLT-2 inhibitors in development for type 2 diabetes treatment

@en

SGLT-2 inhibitors in development for type 2 diabetes treatment

@nl

prefLabel

SGLT-2 inhibitors in development for type 2 diabetes treatment

@ast

SGLT-2 inhibitors in development for type 2 diabetes treatment

@en

SGLT-2 inhibitors in development for type 2 diabetes treatment

@nl

P1433

Q34248505-473906BE-F694-4816-B43E-3099FC954D9B

P1476

Q34248505-86EA09A4-86A5-4CF2-BACD-AC37BA58386A

P2093

Q34248505-2431F3F0-99C5-4E41-87FC-106DF4F34803

Q34248505-28E0DA02-5AFF-4ABF-831E-B1697FFABCEC

Q34248505-542C0051-2C74-45EC-A138-804115466A61

P2860

Q34248505-0284FA89-346F-4481-A31E-709A6A2E943F

Q34248505-0BB6E093-C753-4A8D-BC43-62C3187F3394

Q34248505-14E43A68-5D09-4614-AD9B-B5F0D39B676C

Q34248505-31D53816-6E32-4697-A791-3C4BF0272A5B

Q34248505-35B3CAD9-7B59-4A38-9B03-1A33CA4ADDA8

Q34248505-472995F6-A363-46E5-9164-033E8D5A22E5

Q34248505-49C00A92-2523-4D6C-B5AD-A81CAFFC18A6

Q34248505-4F72373C-B683-435F-AF1D-677E853F7934

Q34248505-50AA0B99-3951-4734-BFA9-2C8319396E01

Q34248505-538869A3-92C6-46E2-9797-FD8A8E57FB02

P304

Q34248505-ECDA0C99-86A5-462A-B584-8CA84F12DE06

P31

Q34248505-4FBAA374-DC29-41E1-8B8C-178535E10FB8

P356

Q34248505-B4A3C445-A79B-425B-A302-C7DB7D047841

P433

Q34248505-EEB4566F-F81C-4711-941C-53E721163210

P478

Q34248505-6995D9CF-3BBE-4668-81DC-09CD01F17A97

P577

Q34248505-4C24CD8F-7E74-4D11-B3C7-BD9C3796CC53

P5875

Q34248505-9300A294-8AAD-424F-BE76-230B10CED582

P698

Q34248505-705932F9-385B-4A63-9791-FB6A54ACC355

P921

Q34248505-5CFEB3C0-95DA-469D-83D1-B03E75AB56AC

P932

Q34248505-B91E08B4-12F0-49D8-89BF-8078F5F37209

P356

P1433

The review of diabetic studies : RDS

P1476

SGLT-2 inhibitors in development for type 2 diabetes treatment

@en

P2093

Abd A Tahrani

http://www.w3.org/2001/XMLSchema#string

Anthony H Barnett

http://www.w3.org/2001/XMLSchema#string

Mithun Bhartia

http://www.w3.org/2001/XMLSchema#string

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Renal Na(+)-glucose cotransporters

Active sugar transport in health and disease

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

10-year follow-up of intensive glucose control in type 2 diabetes

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Pathogenesis of type 2 diabetes mellitus.

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

P304

348-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1900/RDS.2011.8.348

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221763603

http://www.w3.org/2001/XMLSchema#string

P698

22262072

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3280669

http://www.w3.org/2001/XMLSchema#string